Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sachie Osada"'
Autor:
Yumie Takeshita, Chisato Teramura, Kyoko Kamoshita, Hiroaki Takayama, Hiromi Nakagawa, Yasufumi Enyama, Kiyo‐Aki Ishii, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Sachie Osada, Yoshiaki Tanaka, Kumpei Tokuyama, Toshinari Takamura
Publikováno v:
Journal of Diabetes Investigation, Vol 13, Iss 3, Pp 532-542 (2022)
ABSTRACT Aim Selenoprotein P (SeP, encoded by SELENOP in humans) is a hepatokine that causes insulin resistance in the liver and skeletal muscle. It was found that polyunsaturated fatty acid eicosapentaenoic acid (EPA) downregulates Selenop expressio
Externí odkaz:
https://doaj.org/article/2291939474354f1ba9a6bcaefcac3fa8
Publikováno v:
The Journal of General and Applied Microbiology. 68:71-78
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc0ba0a1541c4c52ff61ee70e4a99f87
https://doi.org/10.2323/jgam.2021.10.004
https://doi.org/10.2323/jgam.2021.10.004
Autor:
Kyoko Kamoshita, Yumie Takeshita, Hiromi Nakagawa, Kiyo-aki Ishii, Sachie Osada, Chisato Teramura, Hiroaki Takayama, Yujiro Nakano, Hisanori Goto, Toshinari Takamura, Yasufumi Enyama, Takeo Tanaka, Yoshiaki Tanaka, Kumpei Tokuyama
Publikováno v:
Journal of Diabetes Investigation. 13:532-542
AIM Selenoprotein P (SeP, encoded by SELENOP in humans) is a hepatokine that causes insulin resistance in the liver and skeletal muscle. It was found that polyunsaturated fatty acid eicosapentaenoic acid (EPA) downregulates Selenop expression by inac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad8abb6db5d32a9df88fdaa13b8153dc
https://doi.org/10.1111/jdi.13699
https://doi.org/10.1111/jdi.13699
Autor:
Yusuke Hara, Tsutomu Shimada, Yoshimichi Sai, Kinya Asahino, Sachie Osada, Masayoshi Nobori, Tomonari Makino
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 46:249-256
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec0246a99a77a9ce8d26c147186f3281
https://doi.org/10.5649/jjphcs.46.249
https://doi.org/10.5649/jjphcs.46.249
Autor:
Sachie Osada, Toshinari Takamura, Yoshiaki Tanaka, Takeo Tanaka, Jun Tanimura, Hiromi Nakagawa, Akihiro Kikuchi, Kumpei Tokuyama
Publikováno v:
Endocrine Journal. 66:615-620
The mechanistic target of rapamycin (mTOR) inhibitor everolimus is an antitumor agent known to cause hyperglycemia. However, the clinical course of everolimus-induced hyperglycemia, its pathophysiological basis, and the treatment strategy are not cle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee099fcdb3cc72c9e681823c2bad8e76
https://doi.org/10.1507/endocrj.ej18-0542
https://doi.org/10.1507/endocrj.ej18-0542
Autor:
Jun Tanimura, Hiromi Nakagawa, Takeo Tanaka, Akihiro Kikuchi, Sachie Osada, Yoshiaki Tanaka, Kumpei Tokuyama, Toshinari Takamura
Publikováno v:
Endocrine Journal; 2019, Vol. 66 Issue 7, p615-620, 6p
Autor:
Junko Ishizaki, Eiko Yokoyama, Sakae Shimizu, Akira Kamiya, Sachie Osada, Masahiro Uchikata, Ken-ichi Miyamoto, Hiroyuki Furukawa, Yukiko Matsushima
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 34:7-12
The major problem in the management of information on adverse events is found in both the clinical trial sponsor and the trial institution. The primary cause is inconsistency in the sponsors and trial institutions due to the use of original managemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbaea9231b9e4bf43d7befd450940f7e
https://doi.org/10.3999/jscpt.34.7
https://doi.org/10.3999/jscpt.34.7
Autor:
Yukiko Matsushima, Masahiro Uchikata, Hiroyuki Furukawa, Ken-ichi Miyamoto, Sachie Osada, Hisashi Bunko, Sakae Shimizu, Eiko Yokoyama, Junko Ishizaki, Shizue Matsuda
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 33:281-286
In order to examine the efficient management method of the vast amount of information on adverseevents, a questionnaire survey on the evaluation organization of adverse events in a clinical trial and the implementation of information technology for i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d38297314c6ae26fd8ef118020c2d632
https://doi.org/10.3999/jscpt.33.6_281
https://doi.org/10.3999/jscpt.33.6_281
Autor:
Ken-ichi Miyamoto, Hiroyuki Furukawa, Junko Ishizaki, Kazuaki Suyama, Shizue Matsuda, Sachie Osada, Masami Kawahara, Sakae Shimizu, Yukiko Matsushima
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 32:35-42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60fc085303a515f67b092523f59ad696
https://doi.org/10.3999/jscpt.32.35
https://doi.org/10.3999/jscpt.32.35
Autor:
Hisashi Bunko, Masahiro Uchikata, Junko Ishizaki, Shizue Matsuda, Hiroyuki Furukawa, Sakae Shimizu, Ken-ichi Miyamoto, Eiko Yokoyama, Sachie Osada, Yukiko Matsushima
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 32:287-294
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f11e1a4ed2a8a35252a4a8a15396cc5b
https://doi.org/10.3999/jscpt.32.6_287
https://doi.org/10.3999/jscpt.32.6_287